We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Vienna, Austria

ESTRO 2025

Session

Lung
Digital Poster
Clinical
Predictors and effects of durvalumab induced pneumonitis on outcomes in patients with LANSCLC treated according to the Pacific protocol.
Sarit Appel, Israel
E25-5
Suitability of Metastatic Lung Cancer for PET-Guided Radiotherapy: A Representative Sampling of NSCLC Patients at Staging
Ottar Schmitz, USA
E25-525
Stereotactic body radiotherapy for oligometastatic mediastinal lymph-nodes: a multicentre retrospective experience
Francesco Cuccia, Italy
E25-546
Cardiac Substructure Dosimetry in Lung Cancer Patients Undergoing Post-Operative Radiotherapy
Pervin Hurmuz, Turkey
E25-593
AFSOS-SFRO guidelines on radiation-induced lung injury
Olivier Cravereau, France
E25-745
Impact of Heart and Lung Dosimetry on RV Function in Lung and Oesophageal Cancer Patients
Arno Hessels, The Netherlands
E25-897
An increased number of chemotherapy cycles during radiochemotherapy prolongs overall survival without increasing early or late toxicity
Anna Simbirova , Germany
E25-906
Serplulimab-Based Induction and Sequential Chemoradiotherapy for Bulky Unresectable Stage III NSCLC: Study Design and Preliminary Results
Wei Huang, China
E25-945
Cardiac Sequelae in Metastatic Non-Small Cell Lung Cancer treated non-concurrently with Immunotherapy and SBRT
Sweekruti Hegde, India
E25-1016
Implementation of treatment planning using 4D CT-based lung ventilation imaging to avoid radiation pneumonitis.
takeshi ito, Japan
E25-1049
Safety and Efficacy of Lattice Spatially Fractionated Radiation Therapy for Thoracic Bulky Tumor
Peng Xu, China
E25-1100
Impact of duration of consolidation durvalumab after definitive chemoradiotherapy and EGFR status on outcomes in locally advanced NSCLC
Hiroshi Doi, Japan
E25-109
Association between Tumor Regression during Radiotherapy and Survival in Lung Cancer: A Systematic Review and Meta-Analysis
Haiyan Peng, China
E25-1117
Resting heart rate elevation and implications for autonomic dysfunction during and after concurrent chemo-radiotherapy in non-small cell lung cancer
Ali Ajdari, USA
E25-1262
NLR does not remain prognostic in sarcopenic lung and oesophageal cancer patients
Alan McWilliam, United Kingdom
E25-1321
Prognostic Impact of Tumor Solid Components in Stereotactic Body Radiotherapy for Clinical Stage Tis–1N0M0 Lung Cancer
Junki Fukuda, Japan
E25-1475
Development of a Breathing Score for Risk Assessment of Local Failure in Lung and Liver SBRT
Lukas Wimmert, Germany
E25-1586
Immune checkpoint inhibition alters patterns of failure in inoperable stage III Non-Small Cell Lung Cancer patients treated with chemoradiotherapy
Julian Taugner, Germany
E25-1592
SBRT for Solitary Pulmonary Nodule (SPN) with or without histological confirmation: long-term outcomes of a mono-institutional experience.
Francesca Di Pressa, Italy
E25-1647
CT-based radiomics for predicting response to chemoradiation in locally advanced lung adenocarcinoma
Erika Chung, Canada
E25-1705
Optimizing postoperative proton radiotherapy in thymic epithelial tumors: added value of breath hold?
Dirk De Ruysscher, The Netherlands
E25-1750
Effects of EGFR-TKIs combined with intracranial radiotherapy in EGFR-mutant Non-Small Cell Lung Cancer patients with brain metastases
Mingfeng He, China
E25-1755
Clinical impact of novel dosimetric parameters on the outcome of Stage III NSCLC treated with radiotherapy: a real-world, single Institution analysis
Francesco Dionisi, Italy
E25-113
Delta changes in 18-FDG PET/CT parameters can prognosticate clinical outcomes in recurrent NSCLC patients who have undergone reirradiation
Brane Grambozov, Austria
E25-1870
TIME TO NEXT TREATMENT FOLLOWING SUB-ABLATIVE PROGRESSION DIRECTED RADIATION THERAPY FOR OLIGOPROGRESSIVE NON-SMALL-CELL LUNG CANCER
Riccardo Ray Colciago, Italy
E25-1889
ADSCaN: A Randomised Phase II study of Accelerated, Dose escalated, Sequential Chemo-radiotherapy in Non-Small Cell Lung Cancer. (ISRCTN47674500)
matthew hatton, United Kingdom
E25-1890
Previous use of chemotherapy or multikinase inhibitor decreases efficacy of Pralsetinib in RET fusion-positive non-small-cell lung cancer
Lei Wang, China
E25-1928
Synergy of Immunotherapy and Radiotherapy in Advanced Lung Cancer: Early Efficacy Outcomes and Translational Implications from the START Study.
Valeria Dionisi, Italy
E25-2089
KRAS status in lung oligometastases treated with Stereotactic Body Radiotherapy (SBRT)
Mauro Loi, Italy
E25-2205
Streamlining Lung Cancer Treatment Planning: AI-Enhanced ATS Nodal Contouring Efficiency
Ciaran Malone, Ireland
E25-2231
Fractal dimension and lacunarity as predictive radiomic features for relapse in pulmonary nodules
MARÍA PAGOLA DIVASSÓN, Spain
E25-2243
Association of mediastinal radiotherapy with lymphocyte kinetics during treatment of locally advanced non-small cell lung cancer
Vaiva Kaveckyte, Denmark
E25-2396
Is there a clinical consequence of CTV omission in SBRT of NSCLC?
Philipp Reinhardt, Switzerland
E25-136
Third-Generation EGFR-TKIs Plus Thoracic Radiotherapy Improves Survival in Patients with EGFR-Mutated Stage IV Non-Small Cell Lung Cancer
Baosheng Li, China
E25-2398
Reirradiation for Lung Cancer: Investigating Toxicity and Outcomes
Corinne Faivre-Finn, United Kingdom
E25-2469
Survey on Turkish Radiation Oncologists' Approach in Small Cell Lung Cancer Brain Metastases: Turkish Radiation Oncology SRS Group (TROD 10-014) Study
Yildiz Güney, Turkey
E25-2589
Stereotactic reirradiation for in-field lung cancer recurrence after SABR: a systematic review and meta-analysis
Kevin Jang, Australia
E25-2597
A deep learning model to predict pathological complete response in nsclc patients undergoing neoadjuvant chemoradiation
claudia tacconi, Italy
E25-2603
Impact of lung lobe proportion in total lung DVH parameters on radiation pneumonitis in definitive radiotherapy for lung cancer
SACHIKO MIURA, Japan
E25-2619
Impact of a repeat whole-body PET/CT in patients with locally advanced non-small cell lung cancer planned for radical radiotherapy
Jose Belderbos, The Netherlands
E25-2652
AI driven multimodal signature to predict overall survival in stage III NSCLC receiving chemoradiation
Edy Ippolito, Italy
E25-2697
Detection of pulmonary cancer specific features during radiotherapy using cone-beam CT radiomics
Takuya Taniguchi, Japan
E25-2708
Multi-centre real-world experience with adjuvant durvalumab after chemoradiotherapy in Non-small Cell Lung Cancer: five-year real-world outcomes
Mohammad Rafiqul Islam, United Kingdom
E25-2802
Individual participant data meta-analysis (IPDMA) and systematic review of radical radiotherapy in oligometastatic Nonsmall cell lung carcinoma(NSCLC)
AJAY KUMAR KONDETI, India
E25-213
PRIMALung (EORTC-1901) preliminary data: PRophylactic cerebral Irradiation (PCI) or active brain MRI surveillance in SCLC patients
Antonin Levy, France
E25-2889
Initial clinical experience of 1.5T MR-Linac guided adaptive SBRT for lung metastases with target intrafraction tracking and gating
MICHELE RIGO, Italy
E25-2926
Lessons from the Pandemic: Impact of COVID-19 on Lung Cancer Care
Manuel Luis Blanco Villar, Spain
E25-2961
5 mm around the adenopathy or inclusion of mediastinal lymph node area for radiotherapy treatment of stage III NSCLC
Emmanuel Fardeau, Belgium
E25-3021
Pathologic Complete Response prediction with Machine Learning using Electronic Health Records (EHRs)
Carlo Greco, Italy
E25-3082
Psychological Impact of Lung Cancer Diagnosis
FATIMA ZAHRA CHRAA, Morocco
E25-3119
SABR One Stop Service for early lung cancer: same-day sim-plan-and-treat single fraction stereotactic ablative radiotherapy
Neil Wallace, Australia
E25-3240
Clinical outcomes of stereotactic body radiotherapy for oligometastatic non-small cell lung cancer: a Japanese institutional study
Nao Mamuro, Japan
E25-3327
2-year local failure rates of single versus multi-fraction SBRT for early-stage primary lung cancer and pulmonary oligometastases
Ishaan Pillay, Australia
E25-3385
The importance of dose spill in lung SABR – a simulation study
Marcel van Herk, United Kingdom
E25-3486
Predicted Outcome Benefits of Static and Dynamic Proton Arc Therapy Compared to Intensity-Modulated Proton Therapy for Non-Small Cell Lung Cancer
Arno Hessels, The Netherlands
E25-216
Multi-omics integrative modelling for SBRT in early-stage non-small cell lung cancer: report on the first 100 patients of the MONDRIAN study
Stefania Volpe, Italy
E25-3521
SBRT for Oligoprogressive metastases to the adrenal gland: A single institute retrospective review
Vibhay Pareek, Canada
E25-3559
Chemo-radiation involving Oral Vinorelbine in Lung Cancer: An Alternative Schedule for Elderly Patients
Jesus Romero Fernandez, Spain
E25-3562
Local control of stereotactic body radiotherapy versus moderate hypofractionation for non-small cell lung cancer lesions
Sara Saufi, Italy
E25-3608
Hypofractionated radiochemotherapy in non-small cell lung cancer in a real-world setting. A single-center experience.
Ricardo Oyarzun Silva, Spain
E25-3633
MULTIDISCIPLINARY APPROACH FOR RESPONSE ASSESSMENT AFTER LUNG STEREOTACTIC RADIATION THERAPY
Giuseppina Apicella, Italy
E25-3652
Prognostic effect of thoracic radiotherapy dose after chemotherapy in extensive stage small cell lung cancer patients
Dilara Öztürk, Turkey
E25-3663
The added value of Ethos HyperSight CBCT imaging in lung cancer radiotherapy: structure visibility and suitability for online adaptive treatments
Stijn van de Schoot, The Netherlands
E25-3706
Correlation of the heart–tumour geometric relationship with heart dose and PTV coverage in lung cancer radiotherapy across multiple planning solutions
Fereshteh Gholami, United Kingdom
E25-3796
Tumor volume changes during stereotactic body radiotherapy of lung tumors under MRI guidance
Cedric Richlitzki, Germany
E25-230
Stereotactic body radiation therapy versus surgery in early-stage Non-Small Cell Lung Cancer. Results in comorbid and no-comorbid population.
Laura Martínez Ávila, Spain
E25-3825
ITV-PTV margin reduction from 5 to 3 mm for SBRT-lung treatment
Chin Loon Ong, The Netherlands
E25-3829
Towards MRI-based biomarkers for prognostic response assessment of adaptive radiotherapy in non-small cell lung cancer (NSCLC)
Martin Niklas, Germany
E25-3870
Serendipitous discovery of a novel pathophysiology for pulmonary hemorrhage following central pulmonary radiotherapy
Andrew Hope, Canada
E25-3872
Encephalic radiatherapy during tyrosine kinase inhibitors in advanced Non-Small Cell Lung Cancer:retrospective real-world analysis of a single centre.
BIANCA SANTO, Italy
E25-3888
Long-term Survival Outcomes of Limited Stage Small Cell Lung Cancer – Experience from the Tertiary Cancer Center of India
ANIL TIBDEWAL, India
E25-3921
Value of Systemic Inflammatory Markers to Predict Treatment Response in Non-Small Cell Lung Cancer Patients Treated with Definitive Chemoradiation
Melisa Bağcı Kılıç, Turkey
E25-3950
Dose Escalation with Simultaneous Integrated Boost Technique in Twice-Daily Radiation Therapy for Limited Stage Small Cell Lung Cancer (LS-SCLC)
Şükran Şenyürek, Turkey
E25-3979
Survival and Toxicity Outcomes Following Radiotherapy in Patients with Lung Cancer and Co-existing Interstitial Lung Disease.
Sarah Bowen Jones, United Kingdom
E25-4029
Influence of Prophylactic Cranial Irradiation in the First-Line Treatment of Limited-Stage Small Cell Lung Cancer (LS-SCLC)
Şükran Şenyürek, Turkey
E25-4058
Single-center experience using moderate hypofractionation within chemoradiotherapy for limited stage small cell lung cancer
Maria del Carmen Saiz Guisasola , Spain
E25-317
risk of atrial fibrillation after radiotherapy for lung cancer : should we consider pulmonary veins as an organ at risk ?
Mouna Ben Rejeb, Tunisia
E25-4080
Case report of the first-in-human two modality radiotherapy treatment in a single plan using biology-guided radiotherapy
Dorine de jong, USA
E25-4098
Cardiac substructures’ dose in stage III NSCLC pts undergoing chemoradio-immunotherapy: retrospective monocentric analysis of acute and late toxicity
anna cappelli, Italy
E25-4113
Integration of daily CBCT imaging and PROMs for offline adaptive radiotherapy in stage III NSCLC: Identifying triggers for treatment adaptation
Susanne Schrof, Germany
E25-4167
the potential of Lung Texture Analysis™ as a quantitative imaging tool in the management of stage III NSCLC
Dino Rubini, Italy
E25-4179
THE ROLE OF LUNG METASTASES DIRECTED SBRT IN DELAYING SYSTEMIC THERAPHY PROGRESSION: A SINGLE INSTUTION ANALYSIS
Marco Lucarelli, Italy
E25-4182
Stereotactic body radiation therapy (SBRT) in patients affected by chronic obstructive pulmonary disease (COPD) and Non-Small Cell Lung Cancer (NSCLC)
Elisabetta Bonzano, Italy
E25-4206
Evaluation of automated treatment planning for volumetric modulated arc therapy in stereotactic body lung radiotherapy
Chin Loon Ong, The Netherlands
E25-4252
High dose reirradiation for intrathoracic relapse of lung cancer: a retrospective experience.
Eugenio Cammareri, Italy
E25-4269
Surgery vs. chemoradiotherapy in early limited-stage small cell lung cancer (T1-2N0M0): A SEER-based database analysis
Ahmed Salem, Jordan
E25-4374
a planning CT radiomics model to predict the risk of radiation pneumonitis after SBRT in early stage lung cancer patients or lung metastasis patients.
YUEN YING LAU, Hong Kong (SAR) China
E25-497
Is the SOCCAR Regimen Now a Standard Treatment?
Jesus Romero Fernandez, Spain
E25-4410
QUALITY OF LIFE AND PHYSICAL ACTIVITY IN NON-METASTATIC LUNG CANCER SURVIVORS
chadia ezzouitina, Morocco
E25-4425
Impact of Immunotherapy in the Treatment of Oligometastatic NSCLC Treated with SBRT to all Metastatic Disease Sites
Eva Ćirić, Slovenia
E25-4465
Development and Clinical Implementation of an Adaptive Workflow for Biology-Guided Radiotherapy Using the PET-Linac Platform
Shahed Badiyan, USA
E25-4571
Dosimetric and Clinical Predictors of Acute Radiation Pneumonitis in Patients Pre-Treated with Immune Checkpoint Inhibitors
Marco Galaverni, Italy
E25-4589
Survival outcomes before and after FDA approval of atezolizumab in extensive-stage small cell lung cancer: A SEER database analysis
Ahmed Salem, Jordan
E25-4610
Outcome of radiotherapy to primary thoracic tumor of metastatic small cell lung cancer
Chin Beng Ho, Taiwan
E25-4642